Актуальность применения высоких доз статинов до и после реваскуляризации миокарда
https://doi.org/10.21518/2079-701X-2016-13-66-69
Аннотация
Проанализированы результаты рандомизированных клинических исследований и метаанализов по оценке роли высоких доз статинов до и после коронарного шунтирования и стентирования. Максимальная доказательная база представлена в исследованиях с использованием аторвастатина. Продемонстрировано существенное снижение риска как ранних, так и поздних сердечно-сосудистых осложнений при использовании высоких доз статинов у больных с различными формами ишемической болезни сердца.
Об авторе
М. В. ЕЖОВ
Российский кардиологический научно-производственный комплекс
Россия
Россия
д.м.н.
Москва
Список литературы
1. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011, 217(1): 3-46.
2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129(25 Suppl 2): S1-45.
3. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio- Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2014, 35(37): 2541-619.
4. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med, 2009, 122: 152- 61.
5. Fernandez SF, Boden WE. Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials. Curr Atheroscler Rep, 2010, 12: 423-31.
6. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK et al. Intensive lipidlowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol, 2008, 51: 1938-43.
7. Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc Drugs Ther, 2016, 30(2): 177-88.
8. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation, 2011, 123: 1622-32.
9. Zhang ZJ, Marroquin OC, Weissfeld JL, Stone RA, Mulukutla SR, Williams DO et al. Beneficial effects of statins after percutaneous coronary intervention. Eur J Cardiovasc Prev Rehabil, 2009, 16: 445-50.
10. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation, 2004, 110: 674-67.
11. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol, 2009, 54: 2157-63.
12. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty). Randomized Trial. J Am Coll Cardiol, 2009, 54: 558-65.
13. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein and low-dose anticoagulation on obstructive changes in saphenous- vein coronary-artery bypass grafts. N Engl J Med, 1997, 336: 153-62.
14. Waters DD, Azar RR. Postscripts from the Post-Coronary Artery Bypass Graft trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation. Circulation 2000, 102: 144-6.
15. Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. Expert Opin Drug Saf, 2009, 8: 559-71.
16. Magovern JA, Moraca RJ, Bailey SH, Dean DA, Simpson KA, Maher TD, et al. Preoperative statin is associated with decreased operative mortality in high risk coronary artery bypass patients. J Cardiothorac Surg, 2010, 24(5): 8.
17. Ouattara A, Benhaoua H, Le Manach Y, Mabrouk-Zerguini N, Itani O, Osman A,et al. Perioperative statin therapy is associated with a significant and dose-dependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth, 2009, 23: 633-8.
18. Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg, 2012, 147: 181-9.
19. Аджиев Р.Н., Ежов М.В., Ильина Л.Н., Афанасьева О.И., Власова Э.Е., Матчин Ю.Г. и др. Влияние афереза липопротеидов в течение первого года после операции коронарного шунтирования на течение атеросклероза в аутовенозных шунтах и нативных коронарных артериях у больных с гиперлипидемией, рефрактерной к медикаментозной терапии. Кардиологический вестник, 2014, 9(3): 70-75. / Adjiev R.N., Ezhov M.V., Ilina L.N., Afanasieva O.I., Vlasova E.E., Matchin Y.G. et al. Effect of lipoproteid apheresis for the first year after the coronary artery bypass surgery on atherosclerosis in autovenous bypasses and native coronary arteries in hyperlipidemia patients refractory to drug therapy. Kardiologichesky Vestnik, 2014, 9 (3): 70-75.
Рецензия
Для цитирования:
ЕЖОВ М.В. Актуальность применения высоких доз статинов до и после реваскуляризации миокарда. Медицинский Совет. 2016;(13):66-69. https://doi.org/10.21518/2079-701X-2016-13-66-69
For citation:
EZHOV M.V. RELEVANCY OF HIGH DOSE STATINS APPLICATION BEFORE AND AFTER MYOCARDIUM REVASCULARIZATION. Meditsinskiy sovet = Medical Council. 2016;(13):66-69. (In Russ.) https://doi.org/10.21518/2079-701X-2016-13-66-69
Просмотров: 553
Послать статью по эл. почте 